SMMT vs AZN vs MRK vs BMY vs IQV

For growth investors, AstraZeneca PLC (AZN) is the stronger pick with 8.

6% revenue growth year-over-year, versus -0. 2% for Bristol-Myers Squibb Company (BMY). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 3x trailing P/E (21. 7x forward), making it the more compelling value choice. Analysts rate Summit Therapeutics Inc. (SMMT) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 3x versus AstraZeneca PLC at 28. 0x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 34x versus Merck & Co. , Inc. 's 1. 02x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Summit Therapeutics Inc.

(SMMT) delivered a total return of +222. 3%, compared to -22. 8% for IQVIA Holdings Inc. (IQV). Over 10 years, the gap is even starker: AZN returned +269. 2% versus BMY's +6. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bristol-Myers Squibb Company (BMY) is the lower-risk stock at 0.

45β versus Summit Therapeutics Inc. 's 1. 74β — meaning SMMT is approximately 284% more volatile than BMY relative to the S&P 500. On balance sheet safety, Summit Therapeutics Inc. (SMMT) carries a lower debt/equity ratio of 3% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AstraZeneca PLC (AZN) is pulling ahead at 8.

6% versus -0. 2% for Bristol-Myers Squibb Company (BMY). On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190. 7% year-over-year, compared to -364. 5% for Summit Therapeutics Inc.. Over a 3-year CAGR, AZN leads at 9. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus 0. 0% for Summit Therapeutics Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus 0. 0% for SMMT. At the gross margin level — before operating expenses — AZN leads at 81. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 34x versus Merck & Co. , Inc. 's 1. 02x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 8. 9x forward P/E versus 21. 7x for Merck & Co. , Inc. — 12. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IQV: 25. 2% to $223. 75.

In this comparison, BMY (4.

4% yield), MRK (2. 9% yield), AZN (1. 8% yield) pay a dividend. SMMT, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), 2. 9% yield, +164. 7% 10Y return). Summit Therapeutics Inc. (SMMT) carries a higher beta of 1. 74 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MRK: +164. 7%, SMMT: +102. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SMMT is a mid-cap quality compounder stock; AZN is a large-cap quality compounder stock; MRK is a large-cap deep-value stock; BMY is a mid-cap deep-value stock; IQV is a mid-cap quality compounder stock. AZN, MRK, BMY pay a dividend while SMMT, IQV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.